readthroughSign in
Sep 1, 2026M&A

BioMarin closes acquisition of Alesta Therapeutics

BioMarin finalized its purchase of Alesta Therapeutics on August 31, 2026, making the company a wholly owned subsidiary.

BioMarin Pharmaceutical Inc. disclosed in an 8-K filed September 1, 2026 that it had completed its acquisition of Alesta Therapeutics B.V. The filing states that on August 31, 2026, the parties to the Purchase Agreement finished the Share Purchase, making Alesta a wholly owned subsidiary of BioMarin.1

The transaction traces back to a Share Purchase Agreement first disclosed in an earlier filing. According to the 8-K, BioMarin had entered into a Share Purchase Agreement with Alesta Therapeutics B.V., a Dutch private limited liability company, along with Alesta's shareholders identified in the agreement, Anaheim SpinCo B.V., also a Dutch private limited liability company, and Shareholder Representative Services LLC acting as representative for the Company Participating Equityholders, with the agreement providing for BioMarin's acquisition of Alesta through a share purchase.1 That earlier agreement was filed with the SEC on August 18, 2026.

The September 1 filing notes that full terms of the deal are not laid out in the 8-K itself. The description of the Purchase Agreement and the related transactions is not complete and is instead governed by the full text of the agreement, which was filed as an exhibit to the August 18, 2026 Form 8-K and is incorporated by reference.1

The filing was signed by G. Eric Davis, BioMarin's Executive Vice President and Chief Legal Officer, dated September 1, 2026. BioMarin is headquartered in San Rafael, California, and trades on the Nasdaq Global Select Market under the ticker BMRN.

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.